Reserve Bank of India (RBI) has allowed foreign institutional investors (FIIs) and registered foreign portfolio investors (RFPI) to buy up to 45% stake in Jubilant Life Sciences under the portfolio investment scheme.
The company had earlier received approval from its Board and shareholders for hiking the limit of purchase of its equity shares and convertible debentures by FIIs/RFPIs, who can now buy these instruments through primary and secondary markets.
Jubilant Life Sciences is an integrated global Pharmaceutical and Life Sciences Company engaged in manufacture and supply of APIs, Solid Dosage Formulations, Specialty Pharmaceuticals and Life Science Ingredients. It also provides Services in Contract Manufacturing and Drug Discovery Solutions.
